Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2006 Jun;90(6):705-8.
doi: 10.1136/bjo.2005.088278. Epub 2006 Mar 10.

Photographic estimation of the duration of high dose intravitreal triamcinolone in the vitrectomised eye

B R Kosobucki  1 , W R Freeman, L Cheng
Affiliations

Photographic estimation of the duration of high dose intravitreal triamcinolone in the vitrectomised eye

B R Kosobucki et al. Br J Ophthalmol. 2006 Jun.

Abstract

Aim: To determine the duration of residence of triamcinolone in the vitrectomised eye.

Methods: 23 eyes of 23 patients underwent intravitreal injection of high dose (20 mg) decanted triamcinolone acetonide (Kenalog) at the conclusion of vitrectomy surgery or in previously vitrectomised eyes with macular oedema from diabetes, uveitis, cataract surgery, or other surgery.

Results: The median time to disappearance of triamcinolone in the vitrectomised eye was 113 days (95% confidence interval (CI) 85 to 191). In the phakic eyes the median time to disappearance was 191 days (95% CI 148 to 191). In the pseudophakic eyes the median time to disappearance was 102 days (95% CI 85 to 113). This difference was not significant (p = 0.12). There were no cases of endophthalmitis or severe inflammatory reaction. Five eyes (22%) experienced intraocular pressure rise >/=10 mm Hg.

Conclusions: High dose decanted intravitreal triamcinolone has a median residence time of 113 days in the vitrectomised eye. Although this appears to be shorter than in the non-vitrectomised eye, this study suggests that a sufficient duration of action will be present to be clinically useful.

PubMed Disclaimer

Conflict of interest statement

Proprietary interests: none.

References

    1. Tanner V, Kanski J J, Frith P A. Posterior sub‐Tenon's triamcinolone injections in the treatment of uveitis. Eye 199812(Pt 4)679–685. - PubMed
    1. McCluskey P J, Towler H M, Lightman S. Management of chronic uveitis. BMJ 2000320555–558. - PMC - PubMed
    1. Graham R O, Peyman G A. Intravitreal injection of dexamethasone. Treatment of experimentally induced endophthalmitis. Arch Ophthalmol 197492149–154. - PubMed
    1. Peyman G A, Vastine D W, Meisels H I. The experimental and clinical use of intravitreal antibiotics to treat bacterial and fungal endophthalmitis. Doc Ophthalmol 197539183–201. - PubMed
    1. Vastine D W, Peyman G A, Guth S B. Visual prognosis in bacterial endophthalmitis treated with intravitreal antibiotics. Ophthalmic Surg 19791076–83. - PubMed

Publication types